Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APD515 (bethanechol)
- Development stage
- Phase 2
- Lead developer
- Acacia Pharma
- Modality
- Small Molecules
- Administration
- Oromucosal
01
Overview
APD515 is an optimized oromucosal (liquid) formulation of the muscarinic agonist bethanechol, developed for the treatment of xerostomia (dry mouth), particularly in advanced cancer patients and other populations suffering from reduced salivary flow. Bethanechol stimulates salivary glands to produce saliva by acting as a muscarinic receptor agonist. APD515 is designed for application to the inside of the mouth and represents a new, patent-protected use of this well-known medicine. The drug has shown significant efficacy in reducing symptoms of dry mouth compared to placebo in Phase II clinical trials, with a favorable safety profile[4][5][7].
- Other names
- bethanecholbethanechol chloride
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)
Beyond the preview
Go deeper on APD515 (bethanechol).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APD515 (bethanechol).